Pharmacology  ·  Anti-Seizure Drugs

Valproate

Mechanisms, adverse effects, teratogenicity, and key interactions

• Valproate's clinical value comes directly from a pharmacological property that no other anti-seizure drug shares: it operates through three distinct mechanisms simultaneously. Module 2 showed that each sodium channel blocker occupies one mechanism slot. Valproate occupies three — which is why it is the only agent that covers focal, tonic-clonic, absence, and myoclonic seizures in a single drug.
• The three mechanism cards should be read alongside the seizure type map from Module 1. Sodium channel blockade handles focal and generalized tonic-clonic seizures. T-type calcium channel blockade handles absence. Gamma-aminobutyric acid transaminase inhibition raises inhibitory tone broadly. Each pathway independently justifies valproate's use in a different seizure category.
• Both black-box warnings require active management decisions, not just awareness. For hepatotoxicity: the risk is highest in children under 2 on polypharmacy, and liver function monitoring in the first six months is mandatory. The hepatotoxicity is idiosyncratic — it is not dose-related in the same way the teratogenicity is.
• The teratogenicity black box is the most consequential adverse effect in anti-seizure drug prescribing. The neural tube defect rate runs 10 to 20 times the background rate; the neurodevelopmental impairment — lower IQ and increased autism risk — is independent of the structural malformation risk and is documented in the NEAD study through age 6. These are not theoretical risks.
• The interaction card is one-directional: valproate is an inhibitor, not an inducer. It raises the levels of drugs co-administered with it. The lamotrigine interaction doubles the Stevens-Johnson syndrome risk and requires halving the lamotrigine starting dose — the same combination discussed in Module 2, now seen from valproate's side.